SCHEDULE: Fairmount Funds Management Adjusts Oruka Therapeutics Stake

Fairmount Funds Management LLC and its affiliates have filed an amendment to their Schedule 13D, reporting changes in their beneficial ownership of Oruka Therapeutics, Inc. common stock.

Summary

• Fairmount Funds Management LLC, along with its affiliates Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P., have filed Amendment No. 6 to their Schedule 13D concerning Oruka Therapeutics, Inc.
• On July 1, 2026, Fairmount Healthcare Fund II L.P. converted 42,641 shares of Series B Non-Voting Convertible Preferred Stock into 3,553,410 shares of Oruka Therapeutics' common stock.
• This conversion was effected without cash consideration.
• On the same date, July 1, 2026, Fairmount Healthcare Fund II L.P. sold 3,553,410 shares of common stock in a block trade at a price of $84.43 per share.
• The reporting persons collectively beneficially own 14,553,895 shares of common stock, representing 19.47% of the outstanding shares as of July 1, 2026.
• This total includes directly held common stock, shares issuable upon exercise of pre-funded warrants (subject to a 9.99% beneficial ownership limitation), and shares issuable upon conversion of Series B Preferred Stock (subject to a 19.99% beneficial ownership limitation, which reduces to 9.99% if ownership falls to 9.0% or less).
• The filing also notes 19,022 shares of common stock issuable upon exercise of options held by Peter Harwin, though he disclaims beneficial ownership.
• The total number of outstanding shares of common stock as of July 1, 2026, is reported as 74,733,166.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a major holder, although the conversion of preferred stock is a standard financial maneuver.

Positives

• Fairmount Funds Management has actively managed its stake, demonstrating strategic engagement with its investment in Oruka Therapeutics.
• The conversion of preferred stock and subsequent sale of common stock indicate a potential realization of value or portfolio adjustment by the reporting persons.

Negatives

• The sale of a significant block of shares (3,553,410 shares) by Fairmount Healthcare Fund II L.P. could be interpreted as a reduction in confidence or a profit-taking action, potentially impacting market sentiment.
• The beneficial ownership limitations on warrants and preferred stock conversions suggest potential complexities in future share accumulation or control.

Risks

• The beneficial ownership limitation of 9.99% for Pre-Funded Warrants and 19.99% for Series B Preferred Stock could restrict the reporting persons' ability to acquire a larger stake or exert greater control.
• The reduction of the Series B Preferred Stock conversion limitation to 9.99% when ownership falls to 9.0% or less indicates a dynamic ownership structure that could be affected by market conditions or further transactions.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Oruka Therapeutics. However, the reporting persons' beneficial ownership limitations and ongoing management of their stake suggest continued strategic involvement, subject to these constraints.

Management Comments

• Mr. Harwin holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes in publicly traded companies. This amendment by Fairmount Funds Management indicates a substantial shift in their holdings of Oruka Therapeutics, potentially influencing market perception and strategic direction for the company.

Comparison to Industry Standards

• The beneficial ownership limitations (9.99% for warrants, 19.99% for preferred stock) are common mechanisms used by companies to prevent hostile takeovers or to manage dilution. These are standard practices in the biotechnology and pharmaceutical sectors where significant capital raises and complex financing structures are frequent.
• The sale of a large block of shares at a specific price ($84.43) is a typical event for institutional investors adjusting their portfolios. The price itself would need to be compared to Oruka Therapeutics' trading history around July 1, 2026, to assess its significance relative to market benchmarks.

Stakeholder Impact

• Shareholders: The sale of a large block of shares by a significant holder could lead to short-term price pressure. However, the continued substantial ownership by Fairmount Funds Management suggests ongoing strategic interest.
• Management and Board of Directors: The filing does not indicate any direct impact on the company's management or board, but significant shifts in major shareholder positions can influence board dynamics over time.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Monitoring of Fairmount Funds Management's future transactions and beneficial ownership levels in Oruka Therapeutics.
• Observation of Oruka Therapeutics' stock performance following the block trade.

Key Dates

Recommendation

The filing indicates a significant block trade by a major shareholder, which can create short-term price volatility. However, the reporting persons retain a substantial stake (19.47%), suggesting continued strategic interest. Without further information on Oruka Therapeutics' performance or the rationale behind the sale, a 'hold' recommendation is prudent, advising investors to monitor future developments and the company's underlying fundamentals.

Keywords

Schedule 13D, Oruka Therapeutics, Fairmount Funds Management, Beneficial Ownership, Common Stock, Preferred Stock Conversion, Warrants, Block Trade, SEC Filing, Investment Management